Lenoir, W. Frank https://orcid.org/0000-0002-7413-1885
Morgado, Micaela
DeWeirdt, Peter C.
McLaughlin, Megan https://orcid.org/0000-0002-9971-0111
Griffith, Audrey L. https://orcid.org/0000-0001-5552-2939
Sangree, Annabel K. https://orcid.org/0000-0002-0298-1856
Feeley, Marissa N.
Esmaeili Anvar, Nazanin
Kim, Eiru
Bertolet, Lori L.
Colic, Medina https://orcid.org/0000-0003-1442-1589
Dede, Merve
Doench, John G. https://orcid.org/0000-0002-3707-9889
Hart, Traver https://orcid.org/0000-0002-1880-3341
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM130119)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672)
Andrew Sabin Family Foundation
Article History
Received: 30 October 2020
Accepted: 27 October 2021
First Online: 11 November 2021
Competing interests
: J.G.D. consults for Agios, Maze Therapeutics, Microsoft Research, and Pfizer; J.G.D. consults for and has equity in Tango Therapeutics. W.F.L. has equity in Kronos Bio Inc. The remaining authors declare no competing interests.